The coronavirus vaccine from Johnson & Johnson, the company from which the EU plans to buy up to 400 million doses, is about 66% effective according to a global study.
The company - a multinational American corporation founded in 1886 that develops medical equipment, pharmaceuticals and packaged consumer goods - said the vaccine, which requires only one dose, was 85% effective overall in preventing serious illness. She also demonstrated full protection against hospitalization and death. Vaccine efficacy results were based on 43,783 participants.
Most vaccines used worldwide currently require two doses. But single-dose vaccines are significantly easier to distribute to populations, especially in areas where tracking people after the first dose can be a major challenge.
The J&J vaccine transports the "spike" gene into the body, where cells make harmless copies of proteins to fill the immune system in the event of a true virus. The vaccine developed by AstraZeneca and Oxford University works similarly, but requires two doses.
Both AstraZeneca and J&J vaccines can be stored in an ordinary refrigerator, making them easier to transport and use in developing countries.
It should be noted that there was a change of protection depending on the location: The dose was 72% effective in the United States, compared with 66% in Latin America and 57% in South Africa.
- As a rapper he suddenly became the champion of the Covid vaccine
- Kosovo confirms the first cases with the new version of Covid
- Does Covid-19 affect male fertility? Experts demand caution over new studies!
- Why China has started using anal swabs for Covid
- What is known so far about the 4 variants of the coronavirus
- Beyond the numbers: What does it mean if a vaccine is 90% effective?
Sources: Euronews, CNN
